Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma 14Ovarian Neoplasms 6Neoplasms 5Liposarcoma 5Leiomyosarcoma 5Liposarcoma, Myxoid 3Breast Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neoplasms by Site 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Ichthyosis, X-Linked 2Endometrial Neoplasms 2Uterine Neoplasms 1Solitary Fibrous Tumors 1Soft Tissue Neoplasms 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Recurrent High Grade Meningioma 1Pancreatic Neoplasms 1Ovarian Diseases 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Malignant mesenchymal tumor 1

Interventions

Paclitaxel 7Pemetrexed 3Cisplatin 3Carboplatin 3pembrolizumab 2durvalumab 2adavosertib 2Trastuzumab 2Radiotherapy 2Nivolumab 2FANG vaccine 2Docetaxel 2CP protocol 2Brachytherapy 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1niraparib 1larotrectinib 1ipatasertib 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Neoplasms × Trabectedin × Clear all
NCT00050440 2013-01-08

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
50 enrolled
Gynecologic

Carcinoma, Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡